Summit Therapeutics, Inc. (SMMT)
14.62
+0.46
(+3.25%)
USD |
NASDAQ |
Sep 02, 16:00
14.90
+0.28
(+1.92%)
After-Hours: 19:38
Summit Therapeutics Cash from Investing (Quarterly) : 222.41M for June 30, 2026
Cash from Investing (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Cash from Investing (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 222.41M |
| March 31, 2026 | -0.238M |
| December 31, 2025 | -494.96M |
| September 30, 2025 | -1.038M |
| June 30, 2025 | 159.99M |
| March 31, 2025 | 160.11M |
| December 31, 2024 | 88.18M |
| September 30, 2024 | -114.60M |
| June 30, 2024 | -199.64M |
| March 31, 2024 | 19.87M |
| December 31, 2023 | 74.39M |
| September 30, 2023 | -6.388M |
| June 30, 2023 | -9.561M |
| March 31, 2023 | -645.06M |
| December 31, 2022 | -0.0028M |
| September 30, 2022 | 0.0415M |
| June 30, 2022 | -0.2719M |
| March 31, 2022 | -0.361M |
| December 31, 2021 | -0.1142M |
| September 30, 2021 | 0.0057M |
| June 30, 2021 | -0.1523M |
| March 31, 2021 | -0.039M |
| December 31, 2020 | -0.0574M |
| Date | Value |
|---|---|
| September 30, 2020 | -0.0538M |
| June 30, 2020 | -0.1281M |
| March 31, 2020 | -0.1942M |
| January 31, 2020 | |
| October 31, 2019 | |
| July 31, 2019 | |
| April 30, 2019 | |
| January 31, 2019 | -0.3274M |
| October 31, 2018 | -0.006M |
| July 31, 2018 | -0.0312M |
| April 30, 2018 | -0.042M |
| January 31, 2018 | -6.556M |
| October 31, 2017 | -0.0638M |
| July 31, 2017 | -0.1113M |
| April 30, 2017 | -0.3495M |
| January 31, 2017 | -0.054M |
| October 31, 2016 | -0.0162M |
| July 31, 2016 | -0.0291M |
| April 30, 2016 | -0.01M |
| January 31, 2016 | -0.0071M |
| October 31, 2015 | -0.0536M |
| July 31, 2015 | -0.0116M |
| April 30, 2015 | -0.0256M |
Cash From Investing Definition
Represents the net cash flow from the company's investing activities. Investing activities represent the movement in the company's long-term assets.
Cash from Investing (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Cash from Investing (Quarterly) Benchmarks
| NovelStem International Corp. | 0.00 |
| Brainstorm Cell Therapeutics, Inc. | 0.00 |
| Kezar Life Sciences, Inc. | 1.529M |
| Protara Therapeutics, Inc. | 17.75M |
| Clene, Inc. | -0.001M |
Cash from Investing (Quarterly) Related Metrics
| Cash from Operations (Quarterly) | -140.55M |
| Cash from Financing (Quarterly) | 230.57M |
| Free Cash Flow | -458.40M |
| Free Cash Flow Per Share (Quarterly) | -0.1818 |
| Free Cash Flow to Equity (Quarterly) | -141.81M |
| Free Cash Flow to Firm (Quarterly) | -141.46M |
| Free Cash Flow Yield | -4.09% |